Effectiveness of Vaccines and Monoclonal Antibodies Against Respiratory Syncytial Virus: Generic Protocol for Register-Based Cohort Study
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiad484 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Eero Poukka und 11 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus, Human, Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Several immunization products are currently being developed against respiratory syncytial virus (RSV) for children, pregnant females, and older adults, and some products have already received authorization. Therefore, studies to monitor the effectiveness of these products are needed in the following years. To assist researchers to conduct postmarketing studies, we developed a generic protocol for register-based cohort studies to evaluate immunization product effectiveness against RSV-specific and nonspecific outcomes. To conduct a study on the basis of this generic protocol, the researchers can use any relevant databases or healthcare registers that are available at the study site.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare.
- Department of Public Health, Faculty of Medicine, University of Helsinki, Finland.
- Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
- Sanofi Pasteur SA, Lyon, France.
- Pfizer Limited, NewYork, New York.
- Department of Pediatrics, University of Turku and Turku University Hospital, Finland.
ORCID-Profile: Eero Poukka, Topi Turunen, Ulrike Baum, Rolf Kramer, Elizabeth Begier, Lance Presser, Anne Teirlinck, Terho Heikkinen
Zitieren
APA
Poukka, E., van Roekel, C., Turunen, T., Baum, U., Kramer, R., Begier, E., Presser, L., Teirlinck, A., Heikkinen, T., Knol, M., Nohynek, H., & PROMISE Investigators (2024). Effectiveness of Vaccines and Monoclonal Antibodies Against Respiratory Syncytial Virus: Generic Protocol for Register-Based Cohort Study. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad484
Vancouver
Poukka E, van Roekel C, Turunen T, Baum U, Kramer R, Begier E, et al. Effectiveness of Vaccines and Monoclonal Antibodies Against Respiratory Syncytial Virus: Generic Protocol for Register-Based Cohort Study. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad484
BibTeX
@article{Poukka2024,
author = {Poukka, Eero and van Roekel, Caren and Turunen, Topi and Baum, Ulrike and Kramer, Rolf and Begier, Elizabeth and Presser, Lance and Teirlinck, Anne and Heikkinen, Terho and Knol, Mirjam and Nohynek, Hanna and PROMISE Investigators, PROMISE Investigators},
title = {Effectiveness of Vaccines and Monoclonal Antibodies Against Respiratory Syncytial Virus: Generic Protocol for Register-Based Cohort Study},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiad484}
}
EUVIMED